Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2020

Aug 10, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X] Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ] Preliminary Proxy Statement

[ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

[ ] Definitive Proxy Statement

[X] Definitive Additional Materials

[ ] Soliciting Material Pursuant to §240.14a-12

Lineage Cell Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

• (1) Title of each class of securities to which transaction applies:
• (2) Aggregate number of securities to which transaction applies:
• (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
• (4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

• [ ] Fee paid previously with preliminary materials.
• [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
• (1) Amount previously paid:
• (2) Form, schedule or registration statement no.:

(3) Filing party:

(4) Date filed:

-== LINEAGE

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on September 22, 2020, for Lineage Cell Therapeutics, Inc.

This communical to be new of Lerone of Services of Services are and maner we
encoural deceres only a Werline of the programeral in programment on will best we will beed
prox

						participation.	Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials car be distributed by making them available on the Internet. We have chosen to use these procedures for our 2020 Annual Meeting and need YOUF
							If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's annual meeting, please make this request on of before September 12, 2020.
							For a Convenient Way to VIEW Proxy Materials
				- and -
	VOTE Online go to: www.proxydocs.com/LCTX Proxy Materials Available to View or Receive:
	1. Proxy Statement 2. Annual Report
	Printed materials may be requested by one of the following methods:
		INTERNET www.investorelections.com/LCTX		TELEPHONE (866) 648-8133			paper@investorelections.com
			You must use the 12 digit control number located in the shaded gray box below.			· If requesting material by e-mail, piesse send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requisation material.
				ACCOUNT NO.		SHARES
				Company Notice of Annual Meeting
		LINEAGE	Date:	Tuesday, September 22, 2020 Time: 7:30 a.m. (Pacific Time) Place: 2173 Salk Ave., Suite 200, Carlsbad, CA 92008
		The purpose of the Annual Meeting is to take action on the following proposals:
		The Board of Directors recommends that you vote "FOR" the following:
	1. Election of Directors
	Nominees	01 Deborah Andrews 02 Don M. Bailey		03 Neal C. Bradsher 04 Brian M. Culley	05 Alfred D. Kingsley 06 Michael H. Mulroy		07 Angus C. Russell
		The Board of Directors recommends that you vote "FOR" the following:					2. To rathy the appointment of OUM & Co. LLP as the Company's independent registered public accounting firm for the fiscal year ending
	December 31, 2020
		The Board of Directors recommends that you vote "FOR" the following:
		3. To approve, on an advisory basis, the componsation paid to the Company's named executive officers